These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39050978)

  • 61. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
    Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
    Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
    Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
    J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
    Giri A; Bauman JR
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
    Makharadze T; Gogishvili M; Melkadze T; Baramidze A; Giorgadze D; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Li S; Li Y; Kaul M; Quek RGW; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
    J Thorac Oncol; 2023 Jun; 18(6):755-768. PubMed ID: 37001859
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Implications of Satellitosis or In-transit Metastasis in Cutaneous Squamous Cell Carcinoma: A Prognostic Omission in Cancer Staging Systems.
    Smile TD; Ruiz ES; Kus KJB; Murad F; Wei W; Xiong DD; Vidimos AT; Schmults CD; Koyfman SA
    JAMA Dermatol; 2022 Apr; 158(4):390-394. PubMed ID: 35195668
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
    Freemantle N; Xu Y; Wilson FR; Guyot P; Chen CI; Keeping S; Konidaris G; Chan K; Kuznik A; Atsou K; Glowienka E; Pouliot JF; Gullo G; Rietschel P
    Ther Adv Med Oncol; 2022; 14():17588359221105024. PubMed ID: 35747163
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm.
    Goulden S; Shen Q; Coleman RL; Mathews C; Hunger M; Pahwa A; Schade R
    J Health Econ Outcomes Res; 2023; 10(2):53-61. PubMed ID: 37701519
    [No Abstract]   [Full Text] [Related]  

  • 68. Cemiplimab-Induced Hyperosmolar Hyperglycemic State With Concurrent Diabetic Ketoacidosis in a Patient Receiving Treatment for Cutaneous Squamous Cell Carcinoma.
    Pyronneau A; Noronha K; Zucker A; Kennett R; Desai P
    Cureus; 2024 May; 16(5):e60565. PubMed ID: 38764707
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
    Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
    Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
    Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
    Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.
    Hobday SB; Brody RM; Kriegsman B; Basu D; Newman J; Cohen RB; Lukens JN; Singh A; D'Avella CA; Sun L
    JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):918-926. PubMed ID: 35980666
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
    Stenehjem DD; Lubinga SJ; Gupte-Singh K; Zhang Y; Le TK; Penrod JR; Smith CB
    Clin Lung Cancer; 2021 Jan; 22(1):e35-e47. PubMed ID: 33187914
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer.
    Graf RP; Fisher V; Creeden J; Schrock AB; Ross JS; Nimeiri H; Oxnard GR; Klempner SJ
    Cancer Res Commun; 2022 Sep; 2(9):1037-1048. PubMed ID: 36922935
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
    Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Prognostic Role of [
    Filippi L; Proietti I; Petrozza V; Potenza C; Bagni O; Schillaci O
    Cancer Biother Radiopharm; 2024 Feb; 39(1):46-54. PubMed ID: 37883658
    [No Abstract]   [Full Text] [Related]  

  • 76. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
    Lewis KD; Peris K; Sekulic A; Stratigos AJ; Dunn L; Eroglu Z; Chang ALS; Migden MR; Yoo SY; Mohan K; Coates E; Okoye E; Bowler T; Baurain JF; Bechter O; Hauschild A; Butler MO; Hernandez-Aya L; Licitra L; Neves RI; Ruiz ES; Seebach F; Lowy I; Goncalves P; Fury MG
    Ann Oncol; 2024 Feb; 35(2):221-228. PubMed ID: 38072158
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
    Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
    Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada.
    Zereshkian A; Shafi R; Pond GR; Hotte SJ
    J Immunother; 2024 May; 47(4):123-127. PubMed ID: 38230590
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario.
    Di Lorenzo G; Michele A; Silvana L; Bilancia D; Di Trolio R; Iuliucci MR; Ingenito C; Rubino R; Piscosquito A; Caraglia M; Donnarumma M; Costabile F; Conca R; Pisino M; Vaia A; Scafuri L; Verde A; Buonerba C
    Oncol Ther; 2024 Mar; 12(1):147-155. PubMed ID: 38112965
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review.
    Banini M; Salvestrini V; Vultaggio A; Perlato M; Mecheri V; Cerbai C; Scotti V; Matucci A; Mangoni M; Livi L; Bonomo P
    Curr Oncol; 2023 Jul; 30(7):6699-6707. PubMed ID: 37504351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.